<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23534">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02100813</url>
  </required_header>
  <id_info>
    <org_study_id>LP0084-1014</org_study_id>
    <secondary_id>2014-000037-23</secondary_id>
    <nct_id>NCT02100813</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis</brief_title>
  <official_title>Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify the Maximum Tolerated Dose levels of LEO 43204 after once daily treatment for
      two consecutive days and to evaluate efficacy of LEO 43204 in two doses after once daily
      treatment for two consecutive days compared to vehicle
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Part 1: Dose Limiting Toxicity up to and including Day 8</measure>
    <time_frame>8 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Reduction in AK count</measure>
    <time_frame>From baseline to Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Complete clearance of AKs</measure>
    <time_frame>At Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Partial clearance of AKs</measure>
    <time_frame>Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Partial clearance of AKs at Week 8, defined as at least 75% reduction from baseline in the number of clinically visible AKs</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">205</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Part 1: LEO 43204</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open-label, dose escalation, 2 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: LEO 43204 x dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>X dose for 2 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: LEO 43204 Y dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Y dose for 2 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 2 days treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 43204</intervention_name>
    <arm_group_label>Part 1: LEO 43204</arm_group_label>
    <arm_group_label>Part 2: LEO 43204 x dose</arm_group_label>
    <arm_group_label>Part 2: LEO 43204 Y dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Part 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part 1: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the
             full balding scalp.

          -  Part 2: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the
             full balding scalp

        Exclusion Criteria:

          -  Location of the treatment area

               -  within 5 cm of an incompletely healed wound

               -  within 5 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma
                  (SCC)

          -  Prior treatment with ingenol mebutate gel on the treatment area

          -  Lesions in the treatment areas that have

               -  atypical clinical appearance (e.g., hypertrophic, hyperkeratotic or cutaneous
                  horns) and/or

               -  recalcitrant disease (e.g., did not respond to cryotherapy on two previous
                  occasions)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gwinnett Clinical Research Center, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Birgitte Vestbjerg</last_name>
    <phone>+45 44 94 58 88</phone>
    <email>birgitte.vestbjerg@leo-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gwinnett Clinical Research Center, Inc.</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Weiss, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jonathan Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>March 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
